. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol. 2006 Jan;63(1):49-54. PubMed.

Recommends

Please login to recommend the paper.

Comments

Make a Comment

To make a comment you must login or register.

Comments on this content

No Available Comments

This paper appears in the following:

News

  1. Memantine—Good for a Year, But Little Disease Modification

Webinars

  1. Memantine: Implications for Treating Alzheimer's